Enavogliflozin

Names

[ Name ]:
Enavogliflozin

[Synonym ]:
D-Glucitol, 1,5-anhydro-1-C-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-4-benzofuranyl]-, (1S)-
(1S)-1,5-Anhydro-1-[7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1-benzofuran-4-yl]-D-glucitol

Biological Activity

[Description]:

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].

[Related Catalog]:

Research Areas >> Metabolic Disease

Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT

[Target]

SGLT2

[In Vitro]

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].

[References]

[1]. Daewoong speeds up developing antidiabetic Enavogliflozin

[2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin

[3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong's Enavogliflozin & Janssen Biotech's Golimumab Among Others - ResearchAndMarkets.com

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
666.1±55.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₄H₂₇ClO₆

[ Molecular Weight ]:
446.92

[ Flash Point ]:
356.7±31.5 °C

[ Exact Mass ]:
446.149628

[ LogP ]:
4.90

[ Vapour Pressure ]:
0.0±2.1 mmHg at 25°C

[ Index of Refraction ]:
1.666

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.